Inclusion body myositis (IBM) is an inflammatory myopathy causing proximal and distal muscle weakness. IBM’s cause remains unknown, lacking validated models, biomarkers and effective treatment ...
The most important feature distinguishing inclusion body myositis from the other two inflammatory myopathies is the lack of responsiveness to immunosuppressive treatment. Although most patients ...
The following is a summary of “A systematic review and meta-analysis of the response to placebo in clinical trials of inclusion body myositis,” published in the March 2025 issue of Rheumatology by ...
New research examining the skeletal muscle cells of patients with inclusion body myositis (IBM) has revealed that the nucleic acid-binding protein TDP-43, which is normally restricted to the ...
Dublin, March 05, 2025 (GLOBE NEWSWIRE) -- The "Inclusion Body Myositis - Pipeline ... United States and Europe alone, there is a pressing need for effective treatment options.
US-based biotech Abcuro has raised $200m to advance the development of its monoclonal antibody ulviprubart in the rare muscle disease called inclusion body myositis (IBM). The funding round ...
US biotech Abcuro has reeled in $200 million in third-round financing that should allow it to complete its pivotal trial of lead drug ulviprubart and file it for approval for inclusion body ...
About Inclusion Body Myositis (IBM ... dexterity and mobility. There are currently no available disease-modifying treatment options for IBM. Based on published epidemiology literature, it is ...
Inclusion Body Myositis is a progressive muscle disorder marked ... population exceeding 50,000 in the United States and Europe alone, there is a pressing need for effective treatment options. The ...
Results that may be inaccessible to you are currently showing.
Hide inaccessible results
Feedback